RadNet, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7504911022
USD
81.08
2.28 (2.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About RadNet, Inc. stock-summary
stock-summary
RadNet, Inc.
Pharmaceuticals & Biotechnology
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Company Coordinates stock-summary
Company Details
1510 Cotner Ave , LOS ANGELES CA : 90025-3303
stock-summary
Tel: 1 310 4787808
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 90 Schemes (46.04%)

Foreign Institutions

Held by 127 Foreign Institutions (8.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Howard Berger
Chairman of the Board, President, Chief Executive Officer, Director
Ms. Ruth Wilson
Senior Vice President of Human Resources, Director
Dr. John Crues
Vice President, Medical Director, Director, Corporate Secretary
Mr. David Swartz
Lead Independent Director
Mr. Marvin Cadwell
Independent Director
Mr. Lawrence Levitt
Independent Director
Dr. Michael Sherman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
498 Million
(Quarterly Results - Jun 2025)
Net Profit:
23 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,537 Million (Small Cap)

stock-summary
P/E

137.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.35

stock-summary
Return on Equity

4.80%

stock-summary
Price to Book

5.94